A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Lind, M. J., Cantwell, B. M., Millward, M. J., Robinson, A., Proctor, M., Simmons, D., Carmichael, J., Harris, A. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977567/
https://www.ncbi.nlm.nih.gov/pubmed/1314071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977567/
https://www.ncbi.nlm.nih.gov/pubmed/1314071

Ejemplares similares